Cargando…

Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review

Schizophrenia is among the fifteen most disabling diseases worldwide. Negative symptoms (NS) are highly prevalent in schizophrenia, negatively affect the functional outcome of the disorder, and their treatment is difficult and rarely specifically investigated. Serotonin-dopamine activity modulators...

Descripción completa

Detalles Bibliográficos
Autores principales: Brasso, Claudio, Colli, Gianluca, Sgro, Rodolfo, Bellino, Silvio, Bozzatello, Paola, Montemagni, Cristiana, Villari, Vincenzo, Rocca, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046337/
https://www.ncbi.nlm.nih.gov/pubmed/36979900
http://dx.doi.org/10.3390/biomedicines11030921
_version_ 1785013647656878080
author Brasso, Claudio
Colli, Gianluca
Sgro, Rodolfo
Bellino, Silvio
Bozzatello, Paola
Montemagni, Cristiana
Villari, Vincenzo
Rocca, Paola
author_facet Brasso, Claudio
Colli, Gianluca
Sgro, Rodolfo
Bellino, Silvio
Bozzatello, Paola
Montemagni, Cristiana
Villari, Vincenzo
Rocca, Paola
author_sort Brasso, Claudio
collection PubMed
description Schizophrenia is among the fifteen most disabling diseases worldwide. Negative symptoms (NS) are highly prevalent in schizophrenia, negatively affect the functional outcome of the disorder, and their treatment is difficult and rarely specifically investigated. Serotonin-dopamine activity modulators (SDAMs), of which aripiprazole, cariprazine, brexpiprazole, and lumateperone were approved for schizophrenia treatment, represent a possible therapy to reduce NS. The aim of this rapid review is to summarize the evidence on this topic to make it readily available for psychiatrists treating NS and for further research. We searched the PubMed database for original studies using SDAM, aripiprazole, cariprazine, brexpiprazole, lumateperone, schizophrenia, and NS as keywords. We included four mega-analyses, eight meta-analyses, two post hoc analyses, and 20 clinical trials. Aripiprazole, cariprazine, and brexpiprazole were more effective than placebo in reducing NS. Only six studies compared SDAMs with other classes of antipsychotics, demonstrating a superiority in the treatment of NS mainly for cariprazine. The lack of specific research and various methodological issues, related to the study population and the assessment of NS, may have led to these partial results. Here, we highlight the need to conduct new methodologically robust investigations with head-to-head treatment comparisons and long-term observational studies on homogeneous groups of patients evaluating persistent NS with first- and second-generation scales, namely the Brief Negative Symptom Scale and the Clinical Assessment Interview for Negative Symptoms. This rapid review can expand research on NS therapeutic strategies in schizophrenia, which is fundamental for the long-term improvement of patients’ quality of life.
format Online
Article
Text
id pubmed-10046337
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100463372023-03-29 Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review Brasso, Claudio Colli, Gianluca Sgro, Rodolfo Bellino, Silvio Bozzatello, Paola Montemagni, Cristiana Villari, Vincenzo Rocca, Paola Biomedicines Review Schizophrenia is among the fifteen most disabling diseases worldwide. Negative symptoms (NS) are highly prevalent in schizophrenia, negatively affect the functional outcome of the disorder, and their treatment is difficult and rarely specifically investigated. Serotonin-dopamine activity modulators (SDAMs), of which aripiprazole, cariprazine, brexpiprazole, and lumateperone were approved for schizophrenia treatment, represent a possible therapy to reduce NS. The aim of this rapid review is to summarize the evidence on this topic to make it readily available for psychiatrists treating NS and for further research. We searched the PubMed database for original studies using SDAM, aripiprazole, cariprazine, brexpiprazole, lumateperone, schizophrenia, and NS as keywords. We included four mega-analyses, eight meta-analyses, two post hoc analyses, and 20 clinical trials. Aripiprazole, cariprazine, and brexpiprazole were more effective than placebo in reducing NS. Only six studies compared SDAMs with other classes of antipsychotics, demonstrating a superiority in the treatment of NS mainly for cariprazine. The lack of specific research and various methodological issues, related to the study population and the assessment of NS, may have led to these partial results. Here, we highlight the need to conduct new methodologically robust investigations with head-to-head treatment comparisons and long-term observational studies on homogeneous groups of patients evaluating persistent NS with first- and second-generation scales, namely the Brief Negative Symptom Scale and the Clinical Assessment Interview for Negative Symptoms. This rapid review can expand research on NS therapeutic strategies in schizophrenia, which is fundamental for the long-term improvement of patients’ quality of life. MDPI 2023-03-16 /pmc/articles/PMC10046337/ /pubmed/36979900 http://dx.doi.org/10.3390/biomedicines11030921 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Brasso, Claudio
Colli, Gianluca
Sgro, Rodolfo
Bellino, Silvio
Bozzatello, Paola
Montemagni, Cristiana
Villari, Vincenzo
Rocca, Paola
Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review
title Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review
title_full Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review
title_fullStr Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review
title_full_unstemmed Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review
title_short Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review
title_sort efficacy of serotonin and dopamine activity modulators in the treatment of negative symptoms in schizophrenia: a rapid review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046337/
https://www.ncbi.nlm.nih.gov/pubmed/36979900
http://dx.doi.org/10.3390/biomedicines11030921
work_keys_str_mv AT brassoclaudio efficacyofserotoninanddopamineactivitymodulatorsinthetreatmentofnegativesymptomsinschizophreniaarapidreview
AT colligianluca efficacyofserotoninanddopamineactivitymodulatorsinthetreatmentofnegativesymptomsinschizophreniaarapidreview
AT sgrorodolfo efficacyofserotoninanddopamineactivitymodulatorsinthetreatmentofnegativesymptomsinschizophreniaarapidreview
AT bellinosilvio efficacyofserotoninanddopamineactivitymodulatorsinthetreatmentofnegativesymptomsinschizophreniaarapidreview
AT bozzatellopaola efficacyofserotoninanddopamineactivitymodulatorsinthetreatmentofnegativesymptomsinschizophreniaarapidreview
AT montemagnicristiana efficacyofserotoninanddopamineactivitymodulatorsinthetreatmentofnegativesymptomsinschizophreniaarapidreview
AT villarivincenzo efficacyofserotoninanddopamineactivitymodulatorsinthetreatmentofnegativesymptomsinschizophreniaarapidreview
AT roccapaola efficacyofserotoninanddopamineactivitymodulatorsinthetreatmentofnegativesymptomsinschizophreniaarapidreview